CONTEXT: Hyperuricemia is a predictor for the development of hypertension and is commonly present in new-onset essential hypertension. Experimentally increasing uric acid levels using a uricase inhibitor causes systemic hypertension in animal models. OBJECTIVE: To determine whether lowering uric acid lowers blood pressure (BP) in hyperuricemic adolescents with newly diagnosed hypertension. DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, placebo-controlled, crossover trial (September 2004-March 2007) involving 30 adolescents (aged 11-17 years) who had newly diagnosed, never-treated stage 1 essential hypertension and serum uric acid levels > or = 6 mg/dL. Participants were treated at the Pediatric Hypertension Clinic at Texas Children's Hospital in Houston. Patients were excluded if they had stage 2 hypertension or known renal, cardiovascular, gastrointestinal tract, hepatic, or endocrine disease. INTERVENTION: Allopurinol, 200 mg twice daily for 4 weeks, and placebo, twice daily for 4 weeks, with a 2-week washout period between treatments. The order of the treatments was randomized. MAIN OUTCOME MEASURES: Change in casual and ambulatory blood pressure. RESULTS: For casual BP, the mean change in systolic BP for allopurinol was -6.9 mm Hg (95% confidence interval [CI], -4.5 to -9.3 mm Hg) vs -2.0 mm Hg (95% CI, 0.3 to -4.3 mm Hg; P = .009) for placebo, and the mean change in diastolic BP for allopurinol was -5.1 mm Hg (95% CI, -2.5 to -7.8 mm Hg) vs -2.4 (95% CI, 0.2 to -4.1; P = .05) for placebo. Mean change in mean 24-hour ambulatory systolic BP for allopurinol was -6.3 mm Hg (95% CI, -3.8 to -8.9 mm Hg) vs 0.8 mm Hg (95% CI, 3.4 to -2.9 mm Hg; P = .001) for placebo and mean 24-hour ambulatory diastolic BP for allopurinol was -4.6 mm Hg (-2.4 to -6.8 mm Hg) vs -0.3 mm Hg (95% CI, 2.3 to -2.1 mm Hg; P = .004) for placebo. Twenty of the 30 participants achieved normal BP by casual and ambulatory criteria while taking allopurinol vs 1 participant while taking placebo (P < .001). CONCLUSIONS: In this short-term, crossover study of adolescents with newly diagnosed hypertension, treatment with allopurinol resulted in reduction of BP. The results represent a new potential therapeutic approach, although not a fully developed therapeutic strategy due to potential adverse effects. These preliminary findings require confirmation in larger clinical trials. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00288184.
RCT Entities:
CONTEXT: Hyperuricemia is a predictor for the development of hypertension and is commonly present in new-onset essential hypertension. Experimentally increasing uric acid levels using a uricase inhibitor causes systemic hypertension in animal models. OBJECTIVE: To determine whether lowering uric acid lowers blood pressure (BP) in hyperuricemic adolescents with newly diagnosed hypertension. DESIGN, SETTING, AND PATIENTS: Randomized, double-blind, placebo-controlled, crossover trial (September 2004-March 2007) involving 30 adolescents (aged 11-17 years) who had newly diagnosed, never-treated stage 1 essential hypertension and serum uric acid levels > or = 6 mg/dL. Participants were treated at the Pediatric Hypertension Clinic at Texas Children's Hospital in Houston. Patients were excluded if they had stage 2 hypertension or known renal, cardiovascular, gastrointestinal tract, hepatic, or endocrine disease. INTERVENTION: Allopurinol, 200 mg twice daily for 4 weeks, and placebo, twice daily for 4 weeks, with a 2-week washout period between treatments. The order of the treatments was randomized. MAIN OUTCOME MEASURES: Change in casual and ambulatory blood pressure. RESULTS: For casual BP, the mean change in systolic BP for allopurinol was -6.9 mm Hg (95% confidence interval [CI], -4.5 to -9.3 mm Hg) vs -2.0 mm Hg (95% CI, 0.3 to -4.3 mm Hg; P = .009) for placebo, and the mean change in diastolic BP for allopurinol was -5.1 mm Hg (95% CI, -2.5 to -7.8 mm Hg) vs -2.4 (95% CI, 0.2 to -4.1; P = .05) for placebo. Mean change in mean 24-hour ambulatory systolic BP for allopurinol was -6.3 mm Hg (95% CI, -3.8 to -8.9 mm Hg) vs 0.8 mm Hg (95% CI, 3.4 to -2.9 mm Hg; P = .001) for placebo and mean 24-hour ambulatory diastolic BP for allopurinol was -4.6 mm Hg (-2.4 to -6.8 mm Hg) vs -0.3 mm Hg (95% CI, 2.3 to -2.1 mm Hg; P = .004) for placebo. Twenty of the 30 participants achieved normal BP by casual and ambulatory criteria while taking allopurinol vs 1 participant while taking placebo (P < .001). CONCLUSIONS: In this short-term, crossover study of adolescents with newly diagnosed hypertension, treatment with allopurinol resulted in reduction of BP. The results represent a new potential therapeutic approach, although not a fully developed therapeutic strategy due to potential adverse effects. These preliminary findings require confirmation in larger clinical trials. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00288184.
Authors: Richard J Johnson; Mark S Segal; Titte Srinivas; Ahsan Ejaz; Wei Mu; Carlos Roncal; Laura G Sánchez-Lozada; Michael Gersch; Bernardo Rodriguez-Iturbe; Duk-Hee Kang; Jaime Herrera Acosta Journal: J Am Soc Nephrol Date: 2005-04-20 Impact factor: 10.121
Authors: Arnold B Alper; Wei Chen; Lillian Yau; Sathanur R Srinivasan; Gerald S Berenson; L Lee Hamm Journal: Hypertension Date: 2004-11-29 Impact factor: 10.190
Authors: Giuseppe Mercuro; Cristiana Vitale; Elena Cerquetani; Sandra Zoncu; Martino Deidda; Massimo Fini; Giuseppe M C Rosano Journal: Am J Cardiol Date: 2004-10-01 Impact factor: 2.778
Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237
Authors: Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson Journal: J Biol Chem Date: 2012-10-03 Impact factor: 5.157
Authors: Barbara J Morgan; Mihaela Teodorescu; David F Pegelow; Emily R Jackson; Devin L Schneider; David T Plante; James P Gapinski; Scott J Hetzel; John M Dopp Journal: Exp Physiol Date: 2018-06-08 Impact factor: 2.969
Authors: Yalcin Solak; Hakan Akilli; Mehmet Kayrak; Alpay Aribas; Abduzhappar Gaipov; Suleyman Turk; Santos E Perez-Pozo; Adrian Covic; Kim McFann; Richard J Johnson; Mehmet Kanbay Journal: J Sex Med Date: 2013-09-25 Impact factor: 3.802